- In March 2021, Kiniksa Pharmaceuticals, Ltd. announced that the United States Food and Drug Administration (FDA) approved ARCALYST (rilonacept), a recombinant fusion protein administered weekly via subcutaneous injection. The drug blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling, and is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children aged 12 years and older
- In May 2022, Cardiol Therapeutics revealed that it had received FDA Investigational New Drug (IND) authorization to initiate a multicenter Phase II open-label pilot study of CardiolRx for recurrent pericarditis
